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Abstract
Background: Bacterial meningitis remains an important infection globally, with the greatest burden in children in
low-income settings, including Papua New Guinea (PNG). We present serotype, antimicrobial susceptibility and
outcome data from paediatric meningitis patients prior to introduction of Haemophilus influenzae type b (Hib) and
pneumococcal conjugate vaccines (PCVs) in PNG, providing a baseline for evaluation of immunisation programs.
Methods: Cerebrospinal fluid (CSF) was collected from children admitted to Goroka General Hospital with
suspected meningitis between 1996 and 2005. Culture and sensitivity was conducted, and pneumococci and
H. influenzae were serotyped. Laboratory findings were linked to clinical outcomes.
Results: We enrolled 1884 children. A recognised pathogen was identified in 375 children (19.9 %). Streptococcus
pneumoniae (n = 180) and Hib (n = 153) accounted for 88.8 % of pathogens isolated. 24 different pneumococcal
serogroups were identified; non-PCV types 2, 24 and 46 accounted for 31.6 % of pneumococcal meningitis. 10- and
13-valent PCVs would cover 44.1 % and 45.4 % of pneumococcal meningitis respectively. Pneumococcal isolates
were commonly resistant to penicillin (21.5 %) and 23 % of Hib isolates were simultaneously resistant to ampicillin,
co-trimoxazole and chloramphenicol. The case fatality rate in patients with a recognised bacterial pathogen was
13.4 % compared to 8.5 % in culture-negative patients.
Conclusions: If implemented in routine expanded programme of immunisation (EPI) with high coverage, current
PCVs could prevent almost half of pneumococcal meningitis cases. Given the diversity of circulating serotypes in
PNG serotype replacement is of concern. Ongoing surveillance is imperative to monitor the impact of vaccines. In
the longer term vaccines providing broader protection against pneumococcal meningitis will be needed.
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Background
Bacterial meningitis is an important cause of morbidity
and mortality in children in low-income countries [1]. The
two most important etiological agents of bacterial me-
ningitis are Streptococcus pneumoniae and Haemophilus
influenzae type b (Hib). In total, S. pneumoniae kills over
800,000 children (<5 years old) each year, with meningitis
being the most common severe form of invasive pneumo-
coccal disease (IPD) [2]. Prior to introduction of Hib con-
jugate vaccine there were ~2.2 million cases of serious Hib
disease annually, the vast majority in low-income settings
[3]. In low-income countries the case fatality rate (CFR)
for acute bacterial meningitis is commonly above 30 %
and usually higher for pneumococcal than Hib meningitis
[2, 4–7]. In children who survive acute bacterial meningi-
tis, neurological complications are common with ap-
proximately one in four children in developing countries
suffering long-term neurological sequelae following pneu-
mococcal meningitis [8].
Vaccines have been developed to reduce mortality and
morbidity due to IPD and Hib disease. Hib vaccine is
effective in high and low socio-economic settings. In
The Gambia the incidence of Hib meningitis remains
below 5 cases/100,000 14 years after the introduction of
a three dose course of Hib vaccine [9, 10]. In Indigenous
children in Western Australia the introduction of Hib
vaccine in 1993 resulted in a significant decline in hos-
pital admission for meningitis [11]. Despite the availabil-
ity of conjugate Hib vaccines since the 1980s, there has
been a delay in their inclusion in national immunisation
programs in many low-income countries [12].
The 23-valent pneumococcal polysaccharide vaccine
(PPV) (serotypes 1, 2, 3, 4, 5, 6B, 7 F, 8, 9 N, 9 V, 10, 11,
12 F, 14, 15B, 17 F, 18C, 19 F, 19A, 20, 22 F, 23 and 33 F)
is generally considered to be poorly immunogenic in chil-
dren under 2 years old. The pneumococcal conjugate vac-
cines (PCVs) consist of serotype-specific polysaccharides
conjugated to a protein to improve immunogenicity in
children <2 years old. Introduction of the heptavalent con-
jugate vaccine, PCV7 (serotypes 4, 6B, 9 V, 14, 18C, 19 F
and 23 F) into national immunisation programs has re-
duced the incidence of IPD in a number of industrialised
countries [13, 14]. Studies have demonstrated efficacy of a
9-valent PCV (PCV7 serotypes plus serotypes 1 and 5) in
two African settings [15, 16]. PCV7 has been superseded
in recent years by PCV10 (PCV7 serotypes plus 1, 5 and
7 F) and PCV13 (PCV10 serotypes plus 3, 6A, and 19A).
Rollout of these higher valency vaccines is now occurring
in low-income countries.
Previous studies in PNG have shown S. pneumoniae
and Hib to be the most common causes of bacterial
meningitis and have provided data on serotype distribu-
tion and antimicrobial susceptibility of isolates [6, 17].
With the introduction of Hib vaccine into the PNG
national program in 2008 and rollout of PCV13 com-
mencing in 2014, ongoing surveillance of serotype distri-
bution and antimicrobial susceptibility is essential to
ensure optimal prevention and treatment strategies.
Acute flaccid paralysis surveillance has been conduc-
ted in Goroka in the PNG highlands since 1996 as part
of the global polio eradication campaign. As such, suspec-
ted cases of meningitis have been investigated, providing
data of Hib and pneumococcal meningitis, serotype distri-
bution and antimicrobial susceptibility in the pre-vaccine
era. We report here on data collected from children ad-
mitted to Goroka General Hospital (GGH; now called
Eastern Highlands Provincial Hospital) between August
21st, 1996 and June 17th, 2005.
Methods
Setting and study population GGH is the referral hos-
pital for Eastern Highlands Province (population ~433,000
in 2000) of PNG. The provincial capital Goroka (altitude
1546 m asl) has a population of ~20,000 (70,000 in the
surrounding district). The majority of people are sub-
sistence farmers, with the major cash crop in the province
being coffee.
We have conducted surveillance of suspected meningitis
in children aged <15 years admitted to GGH since 1996.
Case identification was based on any of the following
clinical signs or symptoms: history of convulsion, altered
level of consciousness, neck stiffness, bulging or tense
fontanelle at rest, focal neurological signs associated
with history of recent febrile illness, refusal or inability
to feed associated with a febrile illness, or paediatrician’s
suspicion of meningitis in the absence of above signs
and symptoms. We documented whether patients were
discharged, absconded or died from the hospital records.
Laboratory methods Cerebrospinal fluid (CSF) was col-
lected via lumbar puncture using aseptic technique. Where
possible CSF was collected prior to administration of anti-
biotics in the hospital. Samples were processed at the PNG
Institute of Medical Research (PNGIMR) as soon as
possible after collection. Standard methods, namely mi-
croscopy and bacterial culture were used to diagnose men-
ingitis and determine etiological agents: these methods are
well established in this setting [17]. Microscopy included
cell counts (polymorphonuclear neutrophils, lymphocytes
and erythrocytes) and Gram stain of pelleted CSF. Evi-
dence of prior antimicrobial treatment was garnered
through an assay in which a disk impregnated with the pa-
tient’s CSF was placed on an agar plate seeded with S. aur-
eus ATCC 25923. H. influenzae was serotyped at PNGIMR
using H. influenzae antisera a-f (Remel, Thermo Fisher
Scientific, Australia). Pneumococci were serogrouped at
PNGIMR by the Quellung reaction (Statens Serum Institut,
Copenhagen, Denmark) and a subset sent to Queensland
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Health Pathology Service (Brisbane, Australia) for confirm-
ation and factor typing.
Antibiotic susceptibility testing was conducted by disk
diffusion (Oxoid, Thermo Fisher Scientific, Australia) fol-
lowing CLSI guidelines [18]. Isolates were tested for sus-
ceptibility to chloramphenicol, tetracycline, co-trimoxazole,
ceftriaxone, ampicillin (H. influenzae only), oxacillin (S.
pneumoniae only) and erythromycin (S. pneumoniae only).
Minimum inhibitory concentration (MIC) testing was con-
ducted using E-test (AB Biodisk, Sweden) following CLSI
guidelines [18]. MIC tests were conducted on pneumococ-
cal isolates to determine susceptibility to penicillin, chlor-
amphenicol and cotrimoxazole, with a subset tested for
susceptibility to tetracycline, ceftriaxone and erythromycin.
H. influenzae isolates had MICs determined for ampicillin,
chloramphenicol and cotrimoxazole. At the time this study
was conducted (1996–2005) the MIC for resistance to
penicillin in S. pneumoniae was ≥2 μg/ml (as it remains
currently for non-meningitis cases). CSF pneumococ-
cal isolates now are considered resistant to penicillin
at MIC ≥0.12 μg/ml [18]. We applied the current guide-
lines when determining resistance to penicillin in pneu-
mococcal isolates. Serotyping and sensitivity testing was
conducted at the time of isolation.
Data were double-entered using FoxPro 8 (Microsoft
Corp, USA) and analysed using Excel (Microsoft Corp,
USA). The Yates chi-square test was used to compare
proportions between groups of interest. Ethics approval
was granted by the PNG Medical Research Advisory
Committee to conduct CSF bacterial culture and biochem-
istry as part of the acute flaccid paralysis surveillance. The
need for written informed consent was waivered by the
ethics committee as this work was conducted as part of
good clinical care of the patients.
Results
Between August 1996 and June 2005 CSFs were col-
lected from 1884 patients: 1126 males and 758 females.
The median age of patients was 6 months (lower quartile
3 months, upper quartile 12 months). Bacteria were
isolated from 480 (25.5 %) samples; two organisms were
isolated from five CSF samples, resulting in 485 bacterial
isolates. S. pneumoniae (180) and H. influenzae (165, of
which 153 were Hib) were the most commonly isolated
pathogens, accounting for 91.5 % of recognised pathogens
isolated. Other bacterial pathogens included Enterobacte-
riaceae (14), β-haemolytic streptococci (8) and Acinetobac-
ter spp (6) (Table 1). Thirty-two isolates were considered
probable contaminants: 12 Staphylococcus epidermidis, 10
Bacillus spp., 4 non-aeruginosa pseudomonads, 1 Micro-
coccus sp. and 5 non-specified. A further 76 isolates were
considered possible pathogens (68 Staphylococcus aureus,
5 viridans streptococci, 2 Enterococcus faecalis and 1
Klebsiella oxytoca). The temporal distribution of S. aureus
isolates was indicative of contamination for a large pro-
portion of these isolations: 45 of 68 isolations occurred in
2004 and 2005 and 94.4 % (34 of 36 that had cell count
conducted within this period) occurred in the absence of
polymorphonucleocytes (PMN) in the CSF. In total, 375
CSF (19.9 %) samples were positive for a recognised bac-
terial pathogen (excluding probable contaminants and
possible pathogens). In two of these samples multiple bac-
teria were isolated, resulting in a total of 377 recognised
pathogens, as listed in Table 1.
Of the 1404 culture negative CSF samples, in 263
samples PMN were >10 × 106/l (10–100 × 106/l in 147
samples; >100 × 106/l in 116 samples). We also detected
antimicrobial activity in the CSF of 126 of 1775 samples
tested (including 10 samples with high PMN counts). A
summary of microscopy results is provided in Additional
file 1: Table S1.
Outcomes (died, discharged or absconded) were do-
cumented for 1351 patients (71.7 % of participants). 71
(5 %) children were taken home while still sick. The CFR
during hospitalisation among remaining children was
9.5 %. The CFR for patients in whom a recognised bac-
terial pathogen was isolated (i.e. excluding possible path-
ogens and probable contaminants) was 13.4 % compared
Table 1 Pathogens isolated from CSF of children admitted to
Goroka General Hospital with meningitis. A total of 377
pathogens were isolated, with an additional 108 isolates
considered contaminants (not shown in table)
Pathogen Number
Streptococcus pneumoniae 180
Haemophilus influenzae 165
(Hia 9; Hib 153; Hic 2; NT 1)
Neisseria meningitidis 1
Group A Streptococcus 6
Group B Streptococcus 2
Escherichia coli 4
Klebsiella pneumoniae 3
Enterobacter cloacae 1
Proteus sp. 1
Proteus mirabilis 1
Salmonella sp. 2
Providencia sp.a 1
Citrobacter sp.a 1
Pseudomonas aeruginosa 2
Acinetobacter calcoaceticus 2
Acinetobacter lwoffii 4
Non-haemolytic Streptococcusb 1
Hia, Hib and Hic correspond to the serotype of H. influenzae
NT non-typable
aIsolated from the same CSF sample
bCoinfection with E. coli
Greenhill et al. BMC Infectious Diseases  (2015) 15:485 Page 3 of 8
to a CFR of 8.5 % in patients with no bacterial pathogen
isolated (probable contaminant or no bacteria isolated)
(χ2 = 4.94, degrees of freedom (df) = 1, p = 0.026). The CFR
for pneumococcal meningitis was 15.4 %, and 8.9 % for pa-
tients with Hib meningitis (χ2 = 1.82, df = 1, p = 0.177).
Significant differences in age distribution of pneumococ-
cal and Hib meningitis were noticed (Table 2). Pneumo-
coccal meningitis most frequently occurred in infants
aged < 6 months (52.8 % of all pneumococcal meningitis
compared with 36.2 % of Hib meningitis, χ2 = 8.50, 1df,
p = 0.004) whereas Hib meningitis was most frequent
in children aged 6–11 months (50.0 % of Hib cases com-
pared with 20.0 % of pneumococcal meningitis cases, χ2 =
31.85, 1df, p = 0.000).
Serotype distribution of S. pneumoniae and H. influenzae
Of the 180 pneumococcal isolates, 171 were sero-
grouped; yielding 24 different serogroups (29 serotypes)
and one non-typable isolate (Additional file 2: Table S2).
The most common serogroups were 2 (17.5 % of all ser-
ogrouped isolates), 5 (10.5 %), 46 (8.8 %) and 7 (7.0 %).
The proportion of cases of culture-confirmed pneumo-
coccal meningitis that would be covered by 10- and 13-
valent PCVs and PPV is shown in Fig. 1. Where factor
type was relevant, non-factor-typed isolates were excluded
from analysis, resulting in 152 cases. The PCV10 would
cover 44.1 % of all cases in our setting in PNG; an add-
itional 1.3 % of cases (45.4 %) would be covered by
PCV13.
Hib accounted for 153 (93 %) of the 165 of H. influenzae
isolated from CSF; nine isolates (5.5 %) were serotype a,
two (1.2 %) serotype c and one (0.6 %) non-typable.
Antimicrobial susceptibility
Susceptibility testing was conducted by disk diffusion on
177 S. pneumoniae isolates. Reduced susceptibility to oxa-
cillin was observed in 34 (17.2 %) S. pneumoniae isolates;
resistance to other antibiotics was uncommon. Pneumo-
coccal resistance to penicillin (MIC determined by E-test)
was observed in 21.5 % of isolates (Table 3). Some
serotypes commonly exhibited reduced susceptibility to
penicillin: serogroups/types 19 (5/6 isolates), 6 (9/11), 10
(3/4), 14 (5/8) 24 (4/9) and 9 (2/5). The one pneumococ-
cal isolate with reduced susceptibility to ceftriaxone (sero-
type 14) was also resistant to penicillin and cotrimoxazole;
three other isolates were resistant to both penicillin and
cotrimoxazole. All four tetracycline-resistant S. pneumo-
niae were also resistant to cotrimoxazole; two isolates
were resistant to additional antibiotics (one to penicillin
and one to chloramphenicol).
All 165H. influenzae isolates had β-lactamase test
conducted, and susceptibility testing was conducted by
disk diffusion on 163 isolates. Fifty-three (32.5 %) isolates
were β-lactamase positive. All resistant H. influenzae
isolates were Hib. All β-lactamase positive isolates were
resistant to ampicillin and cotrimoxazole by disk diffusion,
52/53 were also resistant to chloramphenicol and 51/52
resistant to tetracycline. One-hundred and sixty-two iso-
lates had MICs determined for ampicillin, chloramphenicol
and cotrimoxazole. One-third of isolates demonstrated re-
duced susceptibility to ampicillin, with a similar proportion
of isolates having reduced susceptibility to cotrimoxazole
and chloramphenicol (Table 3). Multiple resistance was
common in H. influenzae isolates, with 38 (23 %) isolates
resistant to ampicillin, chloramphenicol and cotrimoxazole.
An additional 15 isolates showed multiple resistance or
intermediate resistance to two or three of those antibiotics.
Only disk diffusion testing was conducted for tetracyc-
line (n = 162) and ceftriaxone (n = 74). Fifty-seven H. influ-
enzae isolates were resistant to tetracycline (35 %) with
one additional isolate demonstrating intermediate resist-
ance. Fifty-two of the tetracycline-resistant isolates were
also resistant to ampicillin, chloramphenicol and cotri-
moxazole. Four isolates (5 %) were non-susceptible to
ceftriaxone.
Analysis was conducted to determine if the rate of
antibiotic resistance increased during the study period,
using the end of 2000 as the approximate mid-point of
the surveillance (Table 4). There was no statistical differ-
ence in the proportion of pneumococci that were resistant
Table 2 Number of samples, male:female ratio, number (isolation rate %) of S. pneumoniae and H. influenzae, total number of
deaths, discharges and case fatality rate (CFR) for different age groups. Pneumococcal serotypes that were isolated more than once
in an age group are listed
Age (mo) Number M:F Pnc (%) Hib (%) Predominant Pnc serogroups (n) Died Discharged CFR
0–5 892 1.60:1 95 (10.7) 55 (6.2) 2 (16); 5 (15); 14 (5); 12 (5); 7(4); 9(4) 54 519 9.4
6–11 452 1.40:1 36 (8.0) 76 (16.8) 2 (5); 24 (5); 46 (4); 7 (3) 24 297 7.5
12–23 187 1.25:1 17 (9.1) 12 (6.4) 6 (4); 2 (2) 18 114 13.6
24–59 197 1.37:1 18 (9.1) 5 (2.5) 18(2) 17 128 11.7
60+ 145 1.56:1 14 (9.0) 4 (2.7) 2 (2); 7 (2); 18 (2) 9 98 8.4
ANR 11 2.67:1 0 (0) 1 (9.1) 0 2 0.0
CFR based on available data in hospital records. Denominator excludes those who absconded
ANR Age not recorded. Pnc: pneumococcus
Greenhill et al. BMC Infectious Diseases  (2015) 15:485 Page 4 of 8
pre-2001 compared to the later period (2001–June 2005).
However, the proportion of H. influenzae that were resist-
ant to ampicillin increased significantly between the two
periods (Table 4).
Discussion
Our data demonstrate the importance of pneumococcus
and Hib in the aetiology of meningitis in PNG; with the
serotype distribution of pathogenic pneumococci and
age of infection having implications for vaccine efficacy.
Potential changes in serotype distribution (post-vaccine)
and antimicrobial susceptibility dictate the need for on-
going surveillance.
Hib accounts for the vast majority of pathogenic H.
influenzae isolated in this setting (and other settings),
enabling the Hib vaccine to have a significant impact on
disease. In contrast, non-PCV13 serogroups/types 2, 8,
12, 18A, 19B, 24 and 46 were amongst the most com-
monly isolated strains of S. pneumoniae, accounting for
>40 % of all pneumococcal isolates in this study. The
broad range of serotypes observed in this study is in
keeping with our earlier study in which Lehmann et al
found so-called ‘adult’ serogroups of pneumococci were
more commonly isolated from CSF of children than
‘paediatric’ serotypes (i.e. 6, 14) [17].
Serotype 2, the most commonly isolated serotype in
this study, has recently been described as a “newly
recognised pneumococcal infection threat” [19]; how-
ever, it has been noted as a major cause of pneumococ-
cal meningitis in PNG for the past 30 years with no
obvious temporal clustering [6, 17]. Saha and colleagues
noted that serotype 2 affected younger children relative
to other serotypes [19]. In contrast, in our study the age
distribution of serotype 2 reflected the pneumococcal iso-
lation rate over the age groups (Table 2 and Additional
file 2: Table S2). Our study provides evidence that sero-
type 2 presents a threat to this region. PCV13 does not
include serotype 2, and upper respiratory tract carriage of
other non-vaccine serotypes of pneumococcus is common
in infants in this setting [20]. Thus, there may be the
potential for an increase in disease due to non-vaccine
serotypes post pneumococcal vaccine introduction in
PNG, as was seen after the introduction of PCV7 in other
settings [21].
Despite the potential for serotype replacement, the over-
all impact of PCVs has been positive, particularly in high
income settings and with broader spectrum (PCV10 and
Table 3 Proportion of S. pneumoniae and H. influenzae isolates with reduced susceptibility to antibiotics, determined by minimum
inhibitory concentration (MIC)
Number tested Intermediate resistant Resistant Median MIC RS isolates
S. pneumoniae (n = 180)
Penicillin 177 NA 38 (21.5 %) 0.25
Cotrimoxazole 176 8 (4.5 %) 7 (4.0 %) 2/38
Tetracycline 96 0 (0 %) 4 (4.2 %) 24
Chloramphenicol 176 NA 4 (2.3 %) 16
Ceftriaxone 124 1 (0.8 %) 0 (0 %) 1
Erythromycin 94 0 (0 %) 0 (0 %) NA
H. influenzae (n = 165)
Ampicillin 162 8 (4.9 %) 46 (28.4 %) 4
Chloramphenicol 162 NA 51 (31.5 %) 16
Cotrimoxazole 162 8 (4.9 %) 55 (34.0 %) >32/608
CLSI breakpoints (μg/ml) for resistance (R) and intermediate resistance (IR) [18]
S. pneumoniae: penicillin R ≥0.12; cotrimoxazole IR =1/19–2/38, R ≥4/76; tetracycline IR =4, R ≥8; chloramphenicol R ≥8; ceftriaxone IR =1, R ≥2; erythromycin IR =0.5, R ≥1
H. influenzae: ampicillin IR =2, R ≥4; chloramphenicol IR =4, R ≥8; cotrimoxazole; IR =1/19–2/38, R ≥4/76
RS reduced susceptibility (intermediate resistance and resistance)
Fig. 1 The proportion of cases with culture-confirmed pneumococcal
meningitis that would be covered by 10vPCV, by the additional
coverage offered by PCV13 and by PPV by age group. The number in
parenthesis (n) represents the number of cases in that age group for
which serogroup/type data are available. In three age groups (<2, 6–11,
and 12–23 months) PCV13 would offer no additional protection above
that of PCV10. The serotype 6A was not tested with 6C antisera,
thus reported as 6A in this analysis
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PCV13) vaccines. It is difficult to make direct comparisons
due to lack of meningitis-specific data, but in high-income
settings PCVs have reduced overall IPD rates by up to
80 % as a result of the better match between serotypes in
PCVs and serotypes causing disease [13]. Even with lower
serotype coverage (relative to high income settings) and
the potential for serotype replacement, a vaccine that of-
fers 40–50 % coverage in a high burden setting will save
lives. When consideration is given to the roll of pneumo-
coccus in pneumonia, the case for immediate PCV rollout
in high-burden settings becomes even stronger.
Our data demonstrate differences in age distribution
and CFR between Hib meningitis and pneumococcal
meningitis (Table 2). The CFRs for laboratory-confirmed
bacterial meningitis was higher than the CFR for pa-
tients in whom no bacterial pathogen was isolated, and
there was a trend towards a higher CFR in patients with
pneumococcal meningitis than in those with H. influenzae
meningitis (though not statistically significant). The CFRs
observed in the current surveillance are a considerable
improvement on those observed previously in the same
setting, when approximately one-third of children with
probable or confirmed bacterial meningitis died [17]. It is
difficult to ascertain the reasons for this decrease in CFR
over the two study periods; though better overall health of
the population resulting in less severe disease, and/or im-
proved management, may be contributing factors.
We observed high and increasing rates of antimicrobial
resistance in Hib isolates. An increase in resistance relative
to our previous study was observed, in which all Hib were
susceptible to ampicillin and chloramphenicol [17]. A
recent study in the lowlands of PNG found all H. influen-
zae CSF isolates tested (n = 14) were chloramphenicol-
resistant [22]. Until recently chloramphenicol was the
first-line treatment for meningitis in children in PNG: due
to increasing resistance of Hib to chloramphenicol,
ceftriaxone has now replaced it as the treatment of choice
[23]. The observation that four Hib isolates were non-
susceptible to ceftriaxone using the disk-diffusion method
is of concern; however MICs were not conducted to con-
firm non-susceptibility (due to loss of viability of the iso-
lates). Resistance to ceftriaxone in Hib remains uncommon
in other settings [24, 25]; nonetheless, ongoing monitoring
of ceftriaxone susceptibility of Hib is imperative given its
current use for treatment of meningitis in PNG.
Penicillin-resistant pneumococci have long been recog-
nised in PNG. In this study 21.5 % of isolates were penicil-
lin resistant: a similar proportion of isolates (7/31; 22.6 %)
had an MIC ≥0.125 μg/ml in the previous study con-
ducted in this setting [17]. Thus, on the basis of current
and previous findings [17, 22], there is no evidence of in-
creasing prevalence of antimicrobial resistant pneumo-
cocci in PNG.
Tetracycline and erythromycin are not well suited for the
treatment of meningitis; however, monitoring resistance to
these antibiotics in pneumococcal isoaltes is of value. With
limited routine diagnostic culture and sensitivity conducted
in PNG, it is important to gain an insight into resistance
patterns for a wide range of antimicrobial agents from rela-
tively few clinical isolates. Moreover, baseline data on
macrolide resistance in malaria endemic settings is of value
as trials are conducted on malaria prophylaxis [26].
Our study provides important data leading up to the
introduction of Hib and PCV vaccines. The Hib vaccine
(introduced in 2008) and the PCV13 (rollout com-
menced in 2014) should reduce the number of cases of
bacterial meningitis. The predominance of pneumococ-
cal meningitis in the first 6 months of life highlights the
need for early protection. In PNG both an accelerated
1-2-3-month PCV schedule (which ties in with PNG’s
standard EPI schedule) and a schedule including a
neonatal dose (0,1 and 2 months) have been shown to be
safe and immunogenic [27] and should assist in protecting
young children from disease caused by vaccine serotypes.
Recent data from GGH show the benefit of the introduc-
tion of Hib vaccination into the national EPI program.
Analysis conducted by our research team [28] reveal that
the isolation rate of Hib from CSF fell significantly from
6.0 % pre-introduction (2004–7) to 0.94 % following intro-
duction (2009–13) (χ2, P < 0.001). There was no change
in the isolation rate of S. pneumoniae over the same
period [28].
We acknowledge that there are some limitations of the
study and resulting data. We isolated higher numbers of
S. aureus than expected. Further investigation indicated
that CSF collection methods were inadequate and likely
to have contributed to high isolation rate of S. aureus in
2004–2005. Some of these isolates, and some or all of
those in previous years (in which no more than 6 were
Table 4 Proportion of S. pneumoniae and H. influenzae (%) with
reduced antimicrobial susceptibility. Bacteria isolated in first half
of study (1996–2000) were compared to those from the second
half of study (2001–2005). Yates chi-square test was used to
compare the proportion of strains that were resistant in the first
half of the study period (1996–2000) with that in the second
half of the study period (2001–2005)
1996–2000 2001–2005 P value
S. pneumoniae
Penicillin 29/116 (25.0) 9/61 (14.8) 0.12
Chloramphenicol 1/115 (0.9) 3/61 (4.9) 0.09
Cotrimoxazole 9/116 (7.8) 6/60 (10.0) 0.64
Tetracycline 2/69 (2.9) 2/27 (7.4) 0.32
H. influenzae
Ampicillin 27/104 (26.0) 27/58 (46.6) 0.01
Chloramphenicol 27/104 (26.0) 24/58 (41.4) 0.04
Cotrimoxazole 35/104 (33.7) 28/58 (48.3) 0.07
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isolated in any given year between 1997 and 2003) may
have been the causative agent of meningitis. Of the 68 S.
aureus isolates, 11 corresponding CSF specimens were
observed to have elevated PMN counts. However, even
in samples with high PMN counts we cannot discount
the possibility of another undetected bacterial pathogen
being the causative agent of meningitis. This cautious
supposition is supported by the fact that elevated PMN
counts were detected in some specimens from which no
bacteria were isolated (Additional file 2: Tables S2 and
Additional file 3: Table S3). Given that S. aureus is rarely
a cause of paediatric meningitis, and is generally associ-
ated with pre-existing abnormalities of the central ner-
vous system or recent surgery (which were not present
in our patients) [29, 30], we concluded that S. aureus
were most likely contaminants.
Our isolation rate of other contaminants (aside from
S. aureus) was <2 %, which is consistent with other CSF
culture studies (e.g. Dunbar et al. [31]). One additional
limitation of our study is that we obtained data from
only one site within PNG, which may not be representa-
tive of the whole country.
The benefits of ongoing multi-site surveillance of bac-
terial diseases in high-burden settings are well recognised;
however, conducting such surveillance is costly and the
level of expertise required is in short supply. At regional
sites non-culture based methods could be applied. How-
ever, antigen detection assays have short-comings, and
currently available culture-independent nucleic acid detec-
tion methods appear to lack the robustness and user-
friendliness required for resource-poor regional settings
[32]. Moreover, neither method enables antimicrobial
susceptibility testing to be conducting (though resist-
ance can be inferred through the detection of genes).
Concerted efforts are required to develop expertise
and methods to enable more widespread and sustain-
able surveillance of S. pneumoniae and H. influenzae
disease and upper respiratory tract carriage, as vaccines
that reduce the impact of these pathogens are introduced
globally.
Conclusions
Meningitis remains an important cause of severe child-
hood illness and death globally. However, vaccines are
now available for two of the bacterial pathogens com-
monly associated with meningitis, namely H. influenzae
type B and up to 13 serotypes of S. pneumoniae. Pre-
vaccine surveillance data is imperative to gain an insight
into the impact of the vaccines when they are introduced.
Our data demonstrate the important role that non-PCV
serotypes play in childhood disease in PNG. While the
introduction of PCV is welcome in PNG, ongoing sur-
veillance is imperative to monitor the role of non-vaccine
serotypes in disease.
Additional files
Additional file 1: Table S1. Overview of microscopy results for cases of
suspected meningitis in children in Goroka, Papua New Guinea. In this
study, unusually high rates of S. aureus positive CSF was detected.
Microscopy results support the notion that S. aureus is likely a
contaminant in the majority of samples from which it was isolated.
(DOCX 15 kb)
Additional file 2: Table S2. Prevalence of serogroups and serotypes of
S. pneumoniae isolated from children with meningitis admitted to Goroka
General Hospital. (DOCX 22 kb)
Additional file 3: Table S3. Comparison of number of
polymorphonucleocytes in CSF samples positive for S. aureus isolation
versus recognised pathogens (S. pneumoniae and H. influenzae), other
pathogens (non-pneumococcus, non-Hi), probable contaminants and
samples from which no bacteria were isolated. There is no evidence of
significance difference between PMN numbers in CSF with S. aureus
compared to CSF with no pathogens isolated. Analysis conducted using a
non-parametric independent samples median test. (DOCX 16 kb)
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